JP2017525684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525684A5 JP2017525684A5 JP2017503919A JP2017503919A JP2017525684A5 JP 2017525684 A5 JP2017525684 A5 JP 2017525684A5 JP 2017503919 A JP2017503919 A JP 2017503919A JP 2017503919 A JP2017503919 A JP 2017503919A JP 2017525684 A5 JP2017525684 A5 JP 2017525684A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- ring atoms
- independently selected
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims 82
- 125000006413 ring segment Chemical group 0.000 claims 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 57
- 125000001072 heteroaryl group Chemical group 0.000 claims 52
- 229910052736 halogen Inorganic materials 0.000 claims 50
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 43
- 125000001424 substituent group Chemical group 0.000 claims 40
- 150000002367 halogens Chemical class 0.000 claims 37
- 125000000623 heterocyclic group Chemical group 0.000 claims 37
- 229910052717 sulfur Inorganic materials 0.000 claims 36
- 229910052760 oxygen Inorganic materials 0.000 claims 29
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 208000030990 Impulse-control disease Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 206010028570 Myelopathy Diseases 0.000 claims 2
- -1 N (R x ) 2 Chemical group 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 240000007817 Olea europaea Species 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 210000001638 cerebellum Anatomy 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 230000010354 integration Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000005040 opiate dependence Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 0 *C(C(*C(C(C(*)C(*)C1*)N1C(C(*)N(*)*)=O)=O)C(N(C(*)C(N(*)*)=O)[Rh])=O)c(c1c2c(*)c(*)c(*)c1*)c(*)[n]2[Re] Chemical compound *C(C(*C(C(C(*)C(*)C1*)N1C(C(*)N(*)*)=O)=O)C(N(C(*)C(N(*)*)=O)[Rh])=O)c(c1c2c(*)c(*)c(*)c1*)c(*)[n]2[Re] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028512P | 2014-07-24 | 2014-07-24 | |
| US62/028,512 | 2014-07-24 | ||
| US201562129388P | 2015-03-06 | 2015-03-06 | |
| US62/129,388 | 2015-03-06 | ||
| PCT/US2015/042070 WO2016014982A1 (en) | 2014-07-24 | 2015-07-24 | N-methyl-d-aspartate receptor modulators and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114862A Division JP2020176124A (ja) | 2014-07-24 | 2020-07-02 | Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017525684A JP2017525684A (ja) | 2017-09-07 |
| JP2017525684A5 true JP2017525684A5 (enExample) | 2018-10-04 |
Family
ID=55163858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503919A Pending JP2017525684A (ja) | 2014-07-24 | 2015-07-24 | Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 |
| JP2020114862A Pending JP2020176124A (ja) | 2014-07-24 | 2020-07-02 | Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114862A Pending JP2020176124A (ja) | 2014-07-24 | 2020-07-02 | Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9994614B2 (enExample) |
| EP (2) | EP3916003A1 (enExample) |
| JP (2) | JP2017525684A (enExample) |
| AU (2) | AU2015292324A1 (enExample) |
| CA (1) | CA2955196A1 (enExample) |
| WO (1) | WO2016014982A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210198315A1 (en) * | 2016-02-01 | 2021-07-01 | Naurex, INC | Process for synthesis of peptide compounds |
| CN107200725B (zh) * | 2016-03-18 | 2021-06-29 | 江苏恒瑞医药股份有限公司 | 稠杂环类衍生物、其制备方法及其在医药上的应用 |
| CN108148113A (zh) * | 2016-12-06 | 2018-06-12 | 深圳先进技术研究院 | 一种nmda受体调控剂四肽衍生物的固相合成方法 |
| CN107474107B (zh) * | 2017-05-18 | 2023-01-17 | 江苏恩华药业股份有限公司 | Glyx-13的制备方法及用于制备glyx-13的化合物 |
| US20200199173A1 (en) * | 2017-07-28 | 2020-06-25 | Naurex, Inc. | Process and intermediates for synthesis of peptide compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59104350A (ja) * | 1982-11-10 | 1984-06-16 | フアルムイタリア・カルロ・エルバ・ソシエタ・ペル・アチオ−ニ | 生物学的に活性なペプチド及びその製造方法，該ペプチドを含む動物用成長促進剤 |
| DE3618407A1 (de) * | 1986-05-31 | 1987-12-03 | Victor Dipl Chem Dr Med Brantl | Pharmakologisch aktive peptide |
| US5763393A (en) * | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US5885958A (en) * | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| WO2007088099A2 (en) * | 2006-01-13 | 2007-08-09 | Oncoreg Ab | Compounds for the treatment of ischemia and neurodegeneration |
| WO2007112492A1 (en) * | 2006-03-31 | 2007-10-11 | The University Of Queensland | Compounds and methods for the treatment of pain |
| BRPI0918868B8 (pt) * | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2011003064A2 (en) * | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| US20110065648A1 (en) * | 2009-09-15 | 2011-03-17 | Maione Theodore E | Advantageous mu-opiate receptor peptide compounds |
| US9101612B2 (en) * | 2010-02-11 | 2015-08-11 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
-
2015
- 2015-07-24 WO PCT/US2015/042070 patent/WO2016014982A1/en not_active Ceased
- 2015-07-24 AU AU2015292324A patent/AU2015292324A1/en not_active Abandoned
- 2015-07-24 CA CA2955196A patent/CA2955196A1/en not_active Abandoned
- 2015-07-24 EP EP21164642.7A patent/EP3916003A1/en not_active Withdrawn
- 2015-07-24 US US15/328,341 patent/US9994614B2/en not_active Expired - Fee Related
- 2015-07-24 JP JP2017503919A patent/JP2017525684A/ja active Pending
- 2015-07-24 EP EP15824872.4A patent/EP3171941B1/en active Active
-
2018
- 2018-05-10 US US15/976,138 patent/US20180258139A1/en not_active Abandoned
-
2020
- 2020-07-02 JP JP2020114862A patent/JP2020176124A/ja active Pending
-
2021
- 2021-02-16 AU AU2021201006A patent/AU2021201006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525684A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2019527203A5 (enExample) | ||
| RU2016137678A (ru) | Соединения с эфирными группами для лечения опосредованных комплементом нарушений | |
| JP2017531020A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2014520072A5 (enExample) | ||
| JP2019513745A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| JP2018519329A5 (enExample) | ||
| JP2014518286A5 (enExample) | ||
| JP2020510091A5 (enExample) | ||
| JP2018511647A5 (enExample) | ||
| JP2017508816A5 (enExample) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2012521994A5 (enExample) | ||
| JP2014509647A5 (enExample) | ||
| RU2018104278A (ru) | Оксистеролы и способы их применения | |
| JP2017533968A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2013533883A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2019507111A5 (enExample) | ||
| JP2016519165A5 (enExample) |